ADP Ribosyltransferase 4 (ART4) Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-ADP Ribosyltransferase 4 (ART4) antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityADP Ribosyltransferase 4 (ART4)
Clonepolyclonal
Host SpeciesRabbit
Reactive Speciesrat
Isotypen/a
Formataffinity purified
Size0.01 mg, 0.02 mg, 0.05 mg
Concentration200ug/ml
ApplicationsWestern Blot (WB), Immunocytochemistry (ICC), Immunohistochemistry (IHC) Formalin/Paraffin, ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThe antibody is a rabbit polyclonal antibody raised against ART4. It has been selected for its ability to recognize ART4 in immunohistochemical staining and western blotting.
ImmunogenImmunoglobulin Type: IgG Quality Control: Content: The quality control contains recombinant ART4 (Tyr51~Cys275) disposed in loading buffer. Usage: 10uL per well when 3,3'-Diaminobenzidine(DAB) as the substrate. 5uL per well when used in enhanced chemilumescent (ECL). Note: The quality control is specifically manufactured as the positive control. Not used for other purposes. Loading Buffer: 100mM Tris(pH8.8), 2% SDS, 200mM NaCl, 50% glycerol,BPB 0.01%, NaN3 0.02%. Conjugated Antibody: The APC con
Other Names[CD297; DO; DOK1; Dombrock blood group carrier molecule; Ecto-ADP-ribosyltransferase 4; ADP-ribosyltransferase C2 and C3 toxin-like 4; Mono(ADP-ribosyl)transferase 4]
Gene, Accession #[ART4], Gene ID: 312806, NCBI: NP_001166980.1, UniProt: F1MA10
Catalog #MBS2033951
Price$110, $125, $175
Order / More InfoADP Ribosyltransferase 4 (ART4) Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.